Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPCX
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
CTRA
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.69% |
| 2 | Industrials | 9.96% |
| 3 | Consumer Discretionary | 8.03% |
| 4 | Healthcare | 7.46% |
| 5 | Financials | 6.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2826
Plug Power
PLUG
$3.17B
| $36K | ﹤0.01% |
13,286
-11,351
| -46% | -$35.7K |
|
2827
Definitive Healthcare
DH
$76.2M
| $32K | ﹤0.01% |
+38,492
| New | +$35.3K |
|
2828
Standard BioTools
LAB
$263M
| $31.7K | ﹤0.01% |
+38,535
| New | +$36.4K |
|
2829
Acumen Pharmaceuticals
ABOS
$229M
| $31.7K | ﹤0.01% |
+11,872
| New | +$29.3K |
|
2830
BWX Technologies
BWXT
$14.4B
| $31.3K | ﹤0.01% |
161
+24
| +18% | +$5K |
|
|
ORBS
2831
Eightco Holdings
ORBS
$341M
| $30.3K | ﹤0.01% |
+43,581
| New | +$39.2K |
|
|
GRSD
2832
Grandstand Ltd
GRSD
$69.8M
| $26.9K | ﹤0.01% |
14,156
-13,385
| -49% | -$41.7K |
|
2833
Gevo
GEVO
$381M
| $26.4K | ﹤0.01% |
17,581
-207,495
| -92% | -$366K |
|
2834
Nautilus Biotechnolgy
NAUT
$121M
| $24.7K | ﹤0.01% |
+13,184
| New | +$34.8K |
|
2835
Goldman Sachs
GS
$303B
| $20.2K | ﹤0.01% |
20
-253,364
| -100% | -$247M |
|
2836
Gossamer Bio
GOSS
$75.6M
| $17.2K | ﹤0.01% |
104,232
-5,818,066
| -98% | -$1.62M |
|
2837
Humacyte
HUMA
$178M
| $16.9K | ﹤0.01% |
+21,610
| New | +$20K |
|
2838
MaxCyte
MXCT
$142M
| $16.7K | ﹤0.01% |
+13,548
| New | +$13.5K |
|
2839
SkinHealth Systems
SKIN
$85M
| $15.8K | ﹤0.01% |
+22,794
| New | +$17.4K |
|
2840
SelectQuote
SLQT
$146M
| $15.1K | ﹤0.01% |
+17,930
| New | +$16.3K |
|
|
SAFX
2841
XCF Global Inc
SAFX
$134M
| $14.2K | ﹤0.01% |
+32,252
| New | +$14.6K |
|
|
ATYR
2842
aTyr Pharma
ATYR
$49.2M
| $13.7K | ﹤0.01% |
23,015
+12,685
| +123% | +$8.29K |
|
|
GENVR
2843
Gen Digital Inc Contingent Value Rights
GENVR
| $13.4K | ﹤0.01% |
+10,354
| New | +$10.8K |
|
2844
Microvision
MVIS
$50.8M
| $13.2K | ﹤0.01% |
+2,692
| New | +$22.2K |
|
2845
Quantum-Si Incorporated
QSI
$183M
| $12.1K | ﹤0.01% |
+13,629
| New | +$13K |
|
2846
Getty Images
GETY
$111M
| $10.6K | ﹤0.01% |
+12,272
| New | +$10.6K |
|
2847
DraftKings
DKNG
$13B
| $8.94K | ﹤0.01% |
+354
| New | +$8.73K |
|
|
CCIXW
2848
DELISTED
Churchill Capital Corp IX Warrant
CCIXW
| $8.87K | ﹤0.01% |
11,374
| – | – |
|
2849
Arena Group
AREN
$43.1M
| $8.36K | ﹤0.01% |
+10,071
| New | +$17.5K |
|
2850
DocGo
DCGO
$43M
| $6.9K | ﹤0.01% |
+13,375
| New | +$7.99K |
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $7.14B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 9.7% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.